Finance

Lists
Why is MGX up 3.77%?
Dive Deeper
MGX:NASDAQ
Metagenomi Therapeutics Inc
$ 1.10
+3.77%
(+0.040) 1D
10-р сарын 1, 14:20:17 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MGX...
Open
$ 1.06
High
$ 1.10
Low
$ 1.06
Mkt. cap
41.55 сая
Avg. vol.
153.55 мян
Volume
96.68 мян
52-wk high
$ 3.95
52-wk low
$ 1.06
EPS
-$ 2.49
Shares outstanding
37.78 сая
No. of employees
113
Open
$ 1.06
High
$ 1.10
Low
$ 1.06
Mkt. cap
41.55 сая
Avg. vol.
153.55 мян
Volume
96.68 мян
52-wk high
$ 3.95
52-wk low
$ 1.06
EPS
-$ 2.49
Shares outstanding
37.78 сая
No. of employees
113
News stories
From web sources and news partners
About Metagenomi Therapeutics Inc
CEO-
Employees113
Founded2016
HeadquartersEmeryville, Калифорни, Америкийн Нэгдсэн Улс
Sector-
Websitemetagenomi.co
Analyst ratings
Based on 4 analysts giving stock ratings to MGX in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for MGX in the last 3 months.
Highest
Current $ 1.10
$ 7.00 (+536.36%)
Average
$ 6.00 (+445.45%)
Lowest
$ 5.00 (+354.55%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
J.P. Morgan
Hold
Maintained
-
-
08/17/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
08/11/2026
Yanan Zhu
Wells Fargo
Buy
Reiterated
$ 7.00
+536.4%
08/11/2026
Keay Nakae
Chardan Capital
Buy
Maintained
$ 5.00
+354.5%
08/10/2026
Geulah Livshits
Chardan Capital
Buy
Maintained
$ 5.00
+354.5%
07/07/2026
Last report
2026 оны 8-р сарын 10
Fiscal period
Q2 2026
EPS / Est. (USD)
-$ 0.73 / -$ 0.52
-40.38%miss
Revenue / Est. (USD)
-257.00 мян / 2.93 сая
-108.76%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
8.66 сая
3.91 сая
1.25 сая
-257.00 мян
Cost of goods sold
25.28 сая
21.50 сая
19.30 сая
22.51 сая
Cost of revenue
25.28 сая
21.50 сая
19.30 сая
22.51 сая
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.22 сая
6.78 сая
6.54 сая
6.00 сая
Operating expense
6.22 сая
6.78 сая
6.54 сая
6.00 сая
Total operating expenses
31.50 сая
28.28 сая
25.84 сая
28.52 сая
Operating income
-22.84 сая
-24.37 сая
-24.59 сая
-28.77 сая
Other non operating income
-2.00 мян
-11.00 мян
-1.00 мян.
35.00 мян
EBT including unusual items
-20.63 сая
-22.49 сая
-23.05 сая
-27.48 сая
EBT excluding unusual items
-20.63 сая
-22.49 сая
-23.05 сая
-27.48 сая
Income tax expense
-234.00 мян
34.00 мян
10.00 мян
-
Effective tax rate
1.13%
-0.15%
-0.04%
-
Other operating expenses
-
-
-
-
Net income
-20.39 сая
-22.53 сая
-23.06 сая
-27.48 сая
Net profit margin
-235.51%
-576.02%
-1,847.68%
10,693.39%
Earnings per share
-0.55
-0.60
-0.61
-0.73
Interest and investment income
2.21 сая
1.88 сая
1.54 сая
1.26 сая
Interest expense
-
-
-
-
Net interest expenses
2.21 сая
1.88 сая
1.54 сая
1.26 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
-21.52 сая
-23.07 сая
-23.31 сая
-27.51 сая
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google аппс